For example, RCTs of glucagon-like peptide-1 receptor agonists (GLP-1RAs), potent agents for the treatment of type 2 diabetes and obesity6,7 with demonstrated cardiovascular benefits,6 have consistently under-enrolled relevant constituencies of potential medication users, leading to gaps in our understanding about the effectiveness of these drugs in many populations.8–13 Moreover, many newer diabetes medications with cardiovascular benefits, including GLP-1RA, are expensive, making their use and accessibility sensitive to treatment coverage policies. This evidence concerns the gene GLP1R and diabetes mellitus.